What D-Vi-Sol Treats: Main Uses and Benefits

D-Vi-Sol, which contains the nutrient Vitamin D (cholecalciferol), is commonly used for managing nutritional support in infants and young children. This product is applied in clinical settings that involve acute or unstable symptom patterns, relevant in contexts involving heightened systemic burden. Supplemental use is considered relevant for easing the overall symptom burden in situations where patients experience nutrient insufficiency, particularly for breastfed infants, as breast milk alone may not provide adequate levels.

This product is applied across domains where additional symptomatic support related to systemic imbalance is needed. The supportive relief provided may assist with managing conditions associated with acute or disruptive episodes, such as those related to symptoms of increased neurological or muscular activity or symptoms linked to organ-specific functional stress. It assists with maintaining functional stability and supports patients during episodes of heightened discomfort. It helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Facts

• Relief for: Symptoms related to physical discomfort
• Assists with: Maintaining functional stability
• Supports: General well-being during symptomatic phases
• Applicable in: Conditions involving episodic or fluctuating manifestations

D-Vi-Sol, containing Cholecalciferol (Vitamin D3), has officially documented usage criteria defined by regulatory authorities, focusing on patient metabolic status and age. The medicine is primarily intended for the infant and pediatric population.

Contraindicated Populations

Use is prohibited for individuals with the following pre-existing conditions, as defined in regulatory labeling:

• Hypervitaminosis D (high Vitamin D levels)
• Hypercalcemia (high calcium levels in the blood)
• Hypercalciuria (high calcium excretion in urine)
• Severe renal impairment or a history of calcium-containing kidney stones
• Hypersensitivity to the active ingredient or any excipients

Restricted and Age-Related Use

Patients with Sarcoidosis require caution and close monitoring of calcium levels due to altered Vitamin D metabolism. Similarly, caution is advised for those with conditions causing malabsorption.

While the liquid drops are intended for infants, specific high-dose formulations of Cholecalciferol are not recommended for children under 12 years of age. During pregnancy and lactation, use is permitted at prophylactic doses, but overdose must be strictly avoided. Cholecalciferol is excreted into breast milk, which must be accounted for if the infant is also receiving supplementation.

Interactions with other medicines and products

Interactions with D-Vi-Sol (cholecalciferol, or Vitamin D3) primarily involve medicines that affect its absorption, metabolism, or impact the body's calcium levels. It is important to disclose all prescription and over-the-counter products, including vitamins and supplements, to a healthcare professional before use.

Product Category/Specific Medicine	Interaction Summary
Anticonvulsants (e.g., Phenytoin, Fosphenytoin)	Certain anticonvulsants can increase the rate at which cholecalciferol is broken down by the liver, potentially reducing its effectiveness and requiring a dose adjustment.
Bile Acid Sequestrants (e.g., Cholestyramine)	These medicines and agents like Orlistat can significantly decrease the absorption of cholecalciferol. Dosing should be separated by at least two hours to minimize this effect.
Thiazide Diuretics (e.g., Hydrochlorothiazide)	Combining these water pills with cholecalciferol can increase the risk of developing hypercalcemia (abnormally high calcium levels) by decreasing calcium excretion in the urine.
Cardiac Glycosides (e.g., Digoxin)	The combination may enhance the risk of developing heart rhythm problems due to the potential for cholecalciferol to cause hypercalcemia at higher doses.

Restriction: To prevent excessive vitamin D intake and hypervitaminosis D, the use of D-Vi-Sol should be carefully considered if the patient is already taking other Vitamin D-containing products, supplements, or calcitriol. Consult with a healthcare professional for guidance on managing these combinations and to establish a monitoring plan.

D-Vi-Sol provides cholecalciferol (Vitamin D3), a pharmacologically inert pro-hormone that requires a precise biological activation sequence to exert its effect. The action is entirely dependent on this conversion and subsequent genomic receptor agonism.

1. Endocrine Activation and Nuclear Receptor Binding

This domain covers the obligatory two-step enzymatic conversion of cholecalciferol into the active hormone, calcitriol, via enzymes like 1-alpha-hydroxylase in the kidney, which then binds to the Vitamin D Receptor (VDR) in the cell nucleus. This binding event initiates gene transcription, which is the first step in the mechanistic cascade that modulates systemic mineral levels.

---

2. Regulation of Calcium and Phosphate Transport

The mechanism regulates mineral balance by upregulating the synthesis of specific transport proteins, such as Calbindin (CaBP), in the gut and kidney. This action increases the efficiency of intestinal absorption of dietary calcium and phosphate, thereby contributing to the maintenance of plasma levels. This physiological adjustment provides the necessary mineral components required for the process of skeletal mineralization.

Official Administration Guidelines

---

Administration Scope

The standardized usage of D-Vi-Sol requires oral administration of a 1.0 mL dose once daily, which delivers 400 International Units (IU) of cholecalciferol. This specific daily volume and IU amount are documented in the product's labeling. The daily dosage must strictly not exceed 1.0 mL, as specified in the administrative guidelines.

Preparation and Administration Specifics

Proper use mandates that the bottle be shaken well prior to each administration to ensure homogeneity. The dose must be accurately measured using only the device provided (calibrated dropper or syringe). The drops can be administered directly into the infant's mouth, or they may be mixed with various liquids such as formula, breast milk, or juice. When the drops are combined with food or liquid, the mixture must be fully consumed within one hour to guarantee the complete dose is received.

Target Population and Duration

This regimen is intended for infants through 12 months of age, particularly those who are exclusively or partially breastfed, as part of a nutritional support plan. The use is typically continuous throughout the infant's first year of life until their nutritional intake from solid food or formula consistently supplies the necessary daily Vitamin D amount.

---

Resulting Procedural Structure

The official protocol dictates a non-variable 1.0 mL daily regimen for infants, structured around the procedural requirements of accurate measurement and flexible intake context. The instructions define the physical steps required to administer the supplement, ensuring the precise delivery of the labeled cholecalciferol dose.

D-Vi-Sol: Recent Clinical Evidence

---

Evidence for the Prevention of Vitamin D Deficiency

Research examining the administration of Cholecalciferol (Vitamin D3) primarily involves short-term Randomized Controlled Trials (RCTs), supported by Systematic Reviews and Meta-analyses. These studies focused on the research context of Vitamin D Deficiency (VDD) and insufficiency in specific pediatric populations.

The research included term and late pre-term infants, with a focus on those who are exclusively or partially breastfed. The core measurement used was serum 25-hydroxyvitamin D [25(OH)D] concentration, a key biochemical marker relevant in evidence describing biochemical status. Studies monitored how this status evolved in observed populations, and research highlights changes measured during the study period.

Evidence on Skeletal Health and Research Gaps

Studies also explored the relationship between supplementation and markers of skeletal health, monitoring the incidence of Nutritional Rickets and measuring indicators such as Bone Mineral Density (BMD). Trial reports indicated that the available evidence was generally insufficient to determine a clear statistical relationship between supplementation and the incidence of hard clinical outcomes like rickets or fracture during the intervention period.

Research highlights that the evidence is limited because trials often rely heavily on surrogate outcomes (like BMD) rather than clinical endpoints. Long-term studies extending observations up to 3 years of age exist, but certainty remains low regarding the long-term outcomes. The overall statistical heterogeneity observed across trial findings further indicates that drawing certain conclusions across all populations remains challenging.

Common questions about D-Vi-Sol (FAQ)

---

Q: Can D-Vi-Sol cause an upset stomach or gas in infants?

A: Gastrointestinal symptoms, such as an upset stomach or diarrhea, have been reported as possible effects related to the use of oral vitamin D supplements in official information. These effects are often temporary, though individual experience can vary, and are not typically associated with the serious reactions that occur only with excessive dosage.

Q: What happens if a dose of D-Vi-Sol is missed?

A: Official instructions for a missed dose indicate that the dose may be administered when remembered. However, if it is nearly time for the next scheduled dose, instructions advise to take only that dose and counsel against the administration of double or extra doses at the same time.

Q: Does D-Vi-Sol have a defined shelf life once the bottle is opened?

A: The official product labeling provides a 'Use By Date' printed on the carton that should be followed. The label requires the product to be kept tightly closed, but it does not typically specify a separate, shorter duration of use (such as a discard date) after the bottle has been first opened.

Q: Are there research findings that support the use of D-Vi-Sol in babies?

A: Official guidance from major pediatric organizations and government health bodies, such as the American Academy of Pediatrics, includes recommendations for vitamin D supplementation in this population. This is based on research that highlights low average vitamin D levels in human breast milk and the general need for adequate intake during early development.

Q: What does official data say about D-Vi-Sol's safety during pregnancy or breastfeeding?

A: Regulatory texts permit the use of Cholecalciferol at prophylactic doses during pregnancy and lactation. Official data confirms that the active ingredient, Cholecalciferol (Vitamin D3), passes into breast milk, and warnings stress that exceeding the recommended dosage must be strictly avoided due to risks of toxicity.

Q: Is D-Vi-Sol widely available without a prescription?

A: Yes, D-Vi-Sol is classified under the Dietary Supplement Health and Education Act (DSHEA) and is available over-the-counter (OTC). This means the product does not typically require a prescription from a healthcare provider for purchase.

Q: Does D-Vi-Sol contain any artificial colors or preservatives?

A: Certain common formulations of D-Vi-Sol are explicitly labeled as being free from artificial colors and do not contain ingredients derived from the most common food allergens, such as milk, eggs, or soy. Product information also often notes the absence of preservatives in the formulation.

Q: Does D-Vi-Sol contain any sugar or artificial sweeteners?

A: Certain formulations of D-Vi-Sol are often labeled as Sugar-Free and free from artificial sweeteners. These products use other excipients, such as glycerin and natural flavor, in the liquid vehicle.

Q: Is D-Vi-Sol considered a medicine or a supplement by regulatory bodies?

A: By regulatory definition in countries like the United States, D-Vi-Sol is classified as a dietary supplement. This means its regulation falls under the rules for food products and is not subject to the strict pre-market approval process that applies to new prescription drugs (medicines).

Q: How does the vitamin D in D-Vi-Sol differ from the vitamin D found naturally in milk?

A: The amount of vitamin D found in human milk is naturally low, while D-Vi-Sol provides a concentrated dose of Cholecalciferol (Vitamin D3) as a supplement. Conversely, infant formula is typically fortified to provide a reliable amount of vitamin D per serving.

Q: Is there a taste or smell to D-Vi-Sol that babies might react to?

A: Official product information describes D-Vi-Sol as being naturally flavored, often with a mild fruit flavor, to assist with the ease of administration for infants.

Q: What is the difference between D-Vi-Sol and Tri-Vi-Sol?

A: Official product information indicates that D-Vi-Sol contains Vitamin D (Cholecalciferol) as the sole vitamin ingredient. Tri-Vi-Sol is a separate product that contains a combination of Vitamins A, C, and D.

Q: Are there any reports of allergies related to D-Vi-Sol?

A: The official safety profile notes that allergic reactions (hypersensitivity) are a possibility with this type of product. Certain formulations are specifically labeled to not contain ingredients derived from the most common food allergens, such as milk or egg.

Q: Is D-Vi-Sol only for infants, or can older children use it too?

A: D-Vi-Sol is specifically formulated and labeled for the infant population (0–12 months) and delivers the daily intake established for that age group. The product's regulatory labeling focuses its use on the infant population.

Q: What is meant by the 'intended population' for D-Vi-Sol?

A: The intended population is described in regulatory guidelines as infants who are exclusively or partially breastfed or those who receive less than the recommended amount of Vitamin D from fortified formula. This defines the specific group for whom the supplement is designed to ensure adequate intake.

Q: Why is vitamin D sometimes called the 'sunshine vitamin'?

A: Vitamin D is commonly referred to as the 'sunshine vitamin' because the human body is able to naturally create the active ingredient, Cholecalciferol, when the skin is exposed to ultraviolet B (UVB) rays from the sun.

Q: What is the function of the other ingredients (excipients) in D-Vi-Sol?

A: The other ingredients, or excipients, listed in the product label, such as glycerin and water, are included to serve as the liquid vehicle or solvent for the active ingredient. They help ensure the Cholecalciferol is properly dissolved and the product maintains stability.

Q: Why is it important to confirm a product's vitamin D content?

A: It is important to confirm the content because the amount of vitamin D needed to maintain bone health and normal calcium metabolism is defined by official Recommended Dietary Allowances (RDAs). Confirming the content helps ensure the correct amount is being administered to meet nutritional requirements.

Q: Is D-Vi-Sol considered a high-potency vitamin D product?

A: The 400 IU per dose is aligned with the adequate intake established for infants, rather than the much larger therapeutic doses sometimes referred to as 'high-potency.' This is the amount generally recommended to meet the daily nutritional needs of infants.

Q: What is the official source of information about D-Vi-Sol’s approval?

A: Because D-Vi-Sol is categorized as a dietary supplement, the official source of information is primarily the product label itself and the regulatory framework of the Dietary Supplement Health and Education Act (DSHEA). Supplements are not subject to the same approval process as new prescription drugs.

Storage Requirements

Official labeling requires D-Vi-Sol (cholecalciferol solution) to be stored at controlled room temperature, generally between 15 C and 30 C (59 F and 86 F). The product must be kept tightly closed in its original container and stored in a dry environment. It is a mandatory requirement to protect the solution from freezing and from exposure to direct light. The container must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Expired or unused D-Vi-Sol should be disposed of through an authorized drug take-back program or pharmaceutical collection site. If a take-back option is unavailable, official guidelines recommend mixing the liquid with an unappealing substance, such as dirt or used coffee grounds, placing the mixture in a sealed bag, and discarding it in the household trash. The product must not be poured down a sink or flushed down the toilet.